Anemocyte offers development and manufacturing services from R&D to GMP to address needs in the field of:

• pDNA – Plasmids for Viral Vector and RNA manufacturing
• mRNA – mRNA manufacturing for Vaccines and Therapies

Our experience:
> 20 years manufacturing innovative Therapies and related starting materials
> 60 years of pharma solutions within our group of CDMOs (Nine Trees Group)

Come and meet our SMEs at booth 209!

For more information please visit our website https://anemocyte.com/

OmniaBio Inc. is a subsidiary of CCRM. OmniaBio’s facility will be Canada’s first and largest commercial-scale CDMO dedicated to cell and gene therapies. Located at McMaster Innovation Park in Hamilton, Ontario, OmniaBio will anchor a biomanufacturing centre of excellence and will open in three phases between 2024 and 2026. Benefitting from CCRM’s existing expertise and established business practices, OmniaBio will complete CCRM’s continuum of process development and manufacturing capabilities by enabling focused support for clients with late clinical phase and commercial supply needs. OmniaBio is supported by the Government of Ontario, via the Invest Ontario Fund. Visit us at omniabio.com.

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades. The company has industry-leading talent, state-of-the-art facilities, and diverse technology platforms, including gene editing, iPSCs, and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp in Waltham, MA, is a purpose-built facility offering process innovation, process sciences, and cGMP manufacturing capabilities. It was designed to support diverse cell and gene therapy products, including autologous, allogeneic, and regenerative medicine cell products such as iPSC and viral vector manufacturing capabilities.

Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 16+ production suites for customization of new programs and tech transferred programs as of September 2022, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Gene and cell therapy, AAV viral vector manufacturing, Plasmid Manufacturing, Lentiviral vector Manufacturing, Commercial Manufacturing, CDMO,  analytical method development, GMP, fill finish, QC/QA release testing, Process Characterization, Regulatory Affairs, Licensing.

AGC Biologics is a global CDMO providing pharmaceutical process development and manufacturing services for protein-based biologics and cell and gene therapies. With seven facilities and teams of scientists across three continents, we have the resources and the available capacity you need to accelerate your race to GMP. From development to clinical trials to full-scale commercialization, we can help you reach your goals at any stage in the drug development and manufacturing process. We specialize in the following modalities and substances: mammalian and microbial-based therapeutic proteins, recombinant DNA, plasmid DNA, viral vectors, Messenger RNA (mRNA), and genetically engineered cells. Our services range from Process Development, Analytical Development, cGMP Manufacturing (both clinical and commercial), Quality Control, and Quality Assurance and Process Validation.

Founded in Indianapolis in 2014, Genezen is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers the following capabilities, building on the company’s expansive knowledge and experience in the industry and working with the nation’s leading institutions:

• Process Development
• Analytical Development
• cGMP Lentiviral and Retroviral Vector Manufacturing
• Patient Sample Testing
• Cell Therapy Manufacturing
• Master Cell Bank Production and Expansion

We leverage our state-of-the-art facility to allow for flexible manufacturing capacity and scale-up supported for both adherent and suspension platforms using producer cell lines, cell factories, and fixed-bed bioreactors. With our goal to lead with science, Genezen’s core mission is to deliver life-changing therapies through flexible support for cell and gene therapies, from early-stage through to the clinic.

Gamma Biosciences is a leading life sciences company providing products and services to support the development and manufacturing of advanced biologic therapies. Our operating companies are committed to advancing the science and art of bioprocessing by delivering market-ready innovation and expertise that helps our customers. Gamma Biosciences encompass biopharmaceutical companies, contract developers and manufacturing companies. Our goal is to safely bring therapies to patients quickly and efficiently. Gamma is a global company with offices and major manufacturing facilities in North America, the U.K. and Belgium.

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.

Asimov builds tools to program living cells. Our mammalian cell engineering platform advances the design and manufacture of biologics and gene therapies. The Asimov lentiviral producer cell line service delivers monoclonal suspension HEK293T-based inducible cell lines containing all necessary elements for VSV-G pseudotyped lentivirus production. The cell line development process takes 3-4 months from DNA synthesis to research cell bank. This process eliminates the need for multiple costly and time-consuming GMP-grade plasmid batches throughout the clinical and commercial stages. 

Autolomous LTD is the market leading developer of critical manufacturing management systems for cell and gene therapies. Autolomous internationally deploys fully integrated, digitized and automated supply chain software solutions. These solutions utilize emerging technologies such as Distributed Ledger Technology (DLT) and Internet of Things (IoT) to ensure compliance with current and future regulatory requirements. As a result, Autolomous enables manufacturers to reduce costs and deliver cell and gene therapies to more patients.

Autolomous’ platform, AutoloMATETM is a business-critical robust digital solution increasing efficiency, scalability and process streamlining of the GMP manufacturing and product release of cell and gene therapies.

Autolomous LTD is headquartered in London.